[ad_1]
More than 32,000 volunteers participated in the tests, mostly from America, but also from Chile and Peru. According to the cited source, no problems were detected regarding the safety of the vaccine or the formation of blood clots, the results being able to offer additional guarantees to the EU states that recently decided to temporarily suspend the administration of serum due to thrombosis in vaccinated . people with AstraZeneca.
The test result would thus confirm the new recommendation of the European Medicines Agency on the use of serum, after which the European states have announced that they will resume the administration of the serum.
The new evidence would also show that the vaccine works just as well when it comes to protecting the elderly, given that a fifth of the participants who received two doses every four weeks were over 65 years old.
Hundreds of thousands of people have been vaccinated with AstraZeneca in the UK and continue to receive this serum on a daily basis, reports BBC News. The vaccine would be approved in the US in a month or two, according to the new results.
The European Medicines Agency on Thursday expressed its conviction that the benefits of the AstraZeneca vaccine outweigh the risks, following the completion of an investigation into cases of thrombosis in some people vaccinated with this serum, which is why more than 10 countries have suspended its use.
“It is safe and effective,” the EMA said, although it did not completely rule out a link between thromboembolic events and the vaccine.
Following the EMA’s verdict, several states, which had suspended the use of the AstraZeneca vaccine, announced that they would resume immunization with this serum, but not Norway, which is awaiting the results of its own investigation. The EMA’s opinion was eagerly awaited because the European Union, in the midst of the crisis, relies on millions of doses of this vaccine developed by the Swedish-British laboratory AstraZeneca.
